Related Experiment Videos
Target hemoglobin in patients with renal failure
1Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow-Klinikum, Berlin, Germany. kai-uwe.eckardt@charite.de
Nephron
|September 11, 2001
Summary
Recombinant erythropoietin (EPO) treats renal anemia, but target hemoglobin levels remain debated. While improving quality of life, normalizing hemoglobin may pose risks in advanced cardiac disease.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Recombinant erythropoietin (EPO) has been used for renal anemia for 15 years.
- Optimal hemoglobin targets for treatment remain controversial.
- Anemia is linked to left-ventricular hypertrophy progression and mortality.
Observation:
- Partial anemia correction improves quality of life.
- Normalization of hemoglobin may further enhance well-being.
- Evidence suggests anemia correction can improve patient prognosis.
Findings:
- Patients with advanced cardiac disease may not benefit from normalized hemoglobin and could be harmed.
- Complete correction may prevent ventricular dilatation in less advanced cardiac disease.
- Current guidelines set a lower hemoglobin target of 11 g/dl.
Implications:
- Early anemia correction is being studied in predialysis patients.
- Many patients do not achieve guideline-recommended hemoglobin levels.
- Significant numbers of patients remain below target hemoglobin, indicating treatment gaps.